Cargando…

Natriuretic peptide vs. clinical information for diagnosis of left ventricular systolic dysfunction in primary care

BACKGROUND: Screening of primary care patients at risk for left ventricular systolic dysfunction by a simple blood-test might reduce referral rates for echocardiography. Whether or not natriuretic peptide testing is a useful and cost-effective diagnostic instrument in primary care settings, however,...

Descripción completa

Detalles Bibliográficos
Autores principales: Koschack, Janka, Scherer, Martin, Lüers, Claus, Kochen, Michael M, Wetzel, Dirk, Kleta, Sibylle, Pouwels, Claudia, Wachter, Rolf, Herrmann-Lingen, Christoph, Pieske, Burkert, Binder, Lutz
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2008
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2267193/
https://www.ncbi.nlm.nih.gov/pubmed/18298821
http://dx.doi.org/10.1186/1471-2296-9-14
_version_ 1782151621486051328
author Koschack, Janka
Scherer, Martin
Lüers, Claus
Kochen, Michael M
Wetzel, Dirk
Kleta, Sibylle
Pouwels, Claudia
Wachter, Rolf
Herrmann-Lingen, Christoph
Pieske, Burkert
Binder, Lutz
author_facet Koschack, Janka
Scherer, Martin
Lüers, Claus
Kochen, Michael M
Wetzel, Dirk
Kleta, Sibylle
Pouwels, Claudia
Wachter, Rolf
Herrmann-Lingen, Christoph
Pieske, Burkert
Binder, Lutz
author_sort Koschack, Janka
collection PubMed
description BACKGROUND: Screening of primary care patients at risk for left ventricular systolic dysfunction by a simple blood-test might reduce referral rates for echocardiography. Whether or not natriuretic peptide testing is a useful and cost-effective diagnostic instrument in primary care settings, however, is still a matter of debate. METHODS: N-terminal pro-brain natriuretic peptide (NT-proBNP) levels, clinical information, and echocardiographic data of left ventricular systolic function were collected in 542 family practice patients with at least one cardiovascular risk factor. We determined the diagnostic power of the NT-proBNP assessment in ruling out left ventricular systolic dysfunction and compared it to a risk score derived from a logistic regression model of easily acquired clinical information. RESULTS: 23 of 542 patients showed left ventricular systolic dysfunction. Both NT-proBNP and the clinical risk score consisting of dyspnea at exertion and ankle swelling, coronary artery disease and diuretic treatment showed excellent diagnostic power for ruling out left ventricular systolic dysfunction. AUC of NT-proBNP was 0.83 (95% CI, 0.75 to 0.92) with a sensitivity of 0.91 (95% CI, 0.71 to 0.98) and a specificity of 0.46 (95% CI, 0.41 to 0.50). AUC of the clinical risk score was 0.85 (95% CI, 0.79 to 0.91) with a sensitivity of 0.91 (95% CI, 0.71 to 0.98) and a specificity of 0.64 (95% CI, 0.59 to 0.67). 148 misclassifications using NT-proBNP and 55 using the clinical risk score revealed a significant difference (McNemar test; p < 0.001) that was based on the higher specificity of the clinical risk score. CONCLUSION: The evaluation of clinical information is at least as effective as NT-proBNP testing in ruling out left ventricular systolic dysfunction in family practice patients at risk. If these results are confirmed in larger cohorts and in different samples, family physicians should be encouraged to rely on the diagnostic power of the clinical information from their patients.
format Text
id pubmed-2267193
institution National Center for Biotechnology Information
language English
publishDate 2008
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-22671932008-03-13 Natriuretic peptide vs. clinical information for diagnosis of left ventricular systolic dysfunction in primary care Koschack, Janka Scherer, Martin Lüers, Claus Kochen, Michael M Wetzel, Dirk Kleta, Sibylle Pouwels, Claudia Wachter, Rolf Herrmann-Lingen, Christoph Pieske, Burkert Binder, Lutz BMC Fam Pract Research Article BACKGROUND: Screening of primary care patients at risk for left ventricular systolic dysfunction by a simple blood-test might reduce referral rates for echocardiography. Whether or not natriuretic peptide testing is a useful and cost-effective diagnostic instrument in primary care settings, however, is still a matter of debate. METHODS: N-terminal pro-brain natriuretic peptide (NT-proBNP) levels, clinical information, and echocardiographic data of left ventricular systolic function were collected in 542 family practice patients with at least one cardiovascular risk factor. We determined the diagnostic power of the NT-proBNP assessment in ruling out left ventricular systolic dysfunction and compared it to a risk score derived from a logistic regression model of easily acquired clinical information. RESULTS: 23 of 542 patients showed left ventricular systolic dysfunction. Both NT-proBNP and the clinical risk score consisting of dyspnea at exertion and ankle swelling, coronary artery disease and diuretic treatment showed excellent diagnostic power for ruling out left ventricular systolic dysfunction. AUC of NT-proBNP was 0.83 (95% CI, 0.75 to 0.92) with a sensitivity of 0.91 (95% CI, 0.71 to 0.98) and a specificity of 0.46 (95% CI, 0.41 to 0.50). AUC of the clinical risk score was 0.85 (95% CI, 0.79 to 0.91) with a sensitivity of 0.91 (95% CI, 0.71 to 0.98) and a specificity of 0.64 (95% CI, 0.59 to 0.67). 148 misclassifications using NT-proBNP and 55 using the clinical risk score revealed a significant difference (McNemar test; p < 0.001) that was based on the higher specificity of the clinical risk score. CONCLUSION: The evaluation of clinical information is at least as effective as NT-proBNP testing in ruling out left ventricular systolic dysfunction in family practice patients at risk. If these results are confirmed in larger cohorts and in different samples, family physicians should be encouraged to rely on the diagnostic power of the clinical information from their patients. BioMed Central 2008-02-25 /pmc/articles/PMC2267193/ /pubmed/18298821 http://dx.doi.org/10.1186/1471-2296-9-14 Text en Copyright © 2008 Koschack et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Koschack, Janka
Scherer, Martin
Lüers, Claus
Kochen, Michael M
Wetzel, Dirk
Kleta, Sibylle
Pouwels, Claudia
Wachter, Rolf
Herrmann-Lingen, Christoph
Pieske, Burkert
Binder, Lutz
Natriuretic peptide vs. clinical information for diagnosis of left ventricular systolic dysfunction in primary care
title Natriuretic peptide vs. clinical information for diagnosis of left ventricular systolic dysfunction in primary care
title_full Natriuretic peptide vs. clinical information for diagnosis of left ventricular systolic dysfunction in primary care
title_fullStr Natriuretic peptide vs. clinical information for diagnosis of left ventricular systolic dysfunction in primary care
title_full_unstemmed Natriuretic peptide vs. clinical information for diagnosis of left ventricular systolic dysfunction in primary care
title_short Natriuretic peptide vs. clinical information for diagnosis of left ventricular systolic dysfunction in primary care
title_sort natriuretic peptide vs. clinical information for diagnosis of left ventricular systolic dysfunction in primary care
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2267193/
https://www.ncbi.nlm.nih.gov/pubmed/18298821
http://dx.doi.org/10.1186/1471-2296-9-14
work_keys_str_mv AT koschackjanka natriureticpeptidevsclinicalinformationfordiagnosisofleftventricularsystolicdysfunctioninprimarycare
AT scherermartin natriureticpeptidevsclinicalinformationfordiagnosisofleftventricularsystolicdysfunctioninprimarycare
AT luersclaus natriureticpeptidevsclinicalinformationfordiagnosisofleftventricularsystolicdysfunctioninprimarycare
AT kochenmichaelm natriureticpeptidevsclinicalinformationfordiagnosisofleftventricularsystolicdysfunctioninprimarycare
AT wetzeldirk natriureticpeptidevsclinicalinformationfordiagnosisofleftventricularsystolicdysfunctioninprimarycare
AT kletasibylle natriureticpeptidevsclinicalinformationfordiagnosisofleftventricularsystolicdysfunctioninprimarycare
AT pouwelsclaudia natriureticpeptidevsclinicalinformationfordiagnosisofleftventricularsystolicdysfunctioninprimarycare
AT wachterrolf natriureticpeptidevsclinicalinformationfordiagnosisofleftventricularsystolicdysfunctioninprimarycare
AT herrmannlingenchristoph natriureticpeptidevsclinicalinformationfordiagnosisofleftventricularsystolicdysfunctioninprimarycare
AT pieskeburkert natriureticpeptidevsclinicalinformationfordiagnosisofleftventricularsystolicdysfunctioninprimarycare
AT binderlutz natriureticpeptidevsclinicalinformationfordiagnosisofleftventricularsystolicdysfunctioninprimarycare